Home › Companies › ROYALTY PHARMA PLC › 2023-2024

ROYALTY PHARMA PLC 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and ROYALTY PHARMA PLC’s Form 8-K, filed June 6, 2024 (Item 5.07 on EDGAR). Page generated November 1, 2026.

17Reported items
408Asset managers
7,337Fund votes
June 6, 2024Meeting date

Results at a glance

Meeting of June 6, 2024: 17 items on ROYALTY PHARMA PLC’s Form 8-K, filed June 6, 2024: 17 without a stated outcome.

Material dissent

None.

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore ROYALTY PHARMA PLC in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by ROYALTY PHARMA PLC

These tallies are ROYALTY PHARMA PLC’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 6, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

ROYALTY PHARMA PLC — official shareholder meeting results, meeting held June 6, 2024
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Support (of votes cast)	Reported outcome	Voting standard
Elect Director: Pablo Legorreta	469,574,048	16,360,957	91,560	--	24,764,077	97%	Not verified	—
Elect Director: Henry Fernandez	467,493,605	18,441,850	91,110	--	24,764,077	96%	Not verified	—
Elect Director: Bonnie Bassler, Ph.D.	480,331,728	5,609,040	85,797	--	24,764,077	99%	Not verified	—
Elect Director: Errol De Souza, Ph.D.	468,014,051	17,919,666	92,848	--	24,764,077	96%	Not verified	—
Elect Director: Catherine Engelbert	482,164,279	3,725,318	136,968	--	24,764,077	99.2%	Not verified	—
Elect Director: David Hodgson	474,265,799	11,668,945	91,821	--	24,764,077	98%	Not verified	—
Elect Director: Ted Love, M.D.	457,219,827	28,488,315	318,423	--	24,764,077	94%	Not verified	—
Elect Director: Gregory Norden	472,819,630	13,114,794	92,141	--	24,764,077	97%	Not verified	—
2. To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers	448,091,225	37,716,521	218,819	--	24,764,077	92%	Not verified	—
3. To ratify the appointment of Ernst & Young LLP, as the Company's independent registered public accounting firm	510,538,774	175,866	76,002	--	--	99.9%	Not verified	—
4. To approve receipt of the Company's U.K. statutory accounts together with the Company's U.K. statutory reports, including the directors' report, the strategic report, the directors' remuneration report and the auditors' report for the fiscal year ended Dece	510,158,489	64,644	567,509	--	--	99.9%	Not verified	—
5. To approve, the Company's U.K. directors' remuneration policy, included in U.K. directors' remuneration report contained in the U.K. Annual Report and Accounts	446,941,633	38,920,774	164,158	--	24,764,077	92%	Not verified	—
6. To approve, on a non-binding advisory basis, the Company's U.K. directors' remuneration report in the U.K. Annual Report and Accounts	448,684,306	37,116,575	225,684	--	24,764,077	92%	Not verified	—
7. To re-appoint Ernst & Young Chartered Accountants as the Company's U.K. statutory auditor under the U.K. Companies Act 2006, to hold office until the conclusion of the next general meeting of shareholders at which the U.K. annual report and accounts are pre	510,533,472	190,241	66,929	--	--	99.9%	Not verified	—
8. To authorize the Board of Directors to determine the remuneration of the Company's U.K. statutory auditor	485,875,260	100,511	50,794	--	24,764,077	99.9%	Not verified	—
9. To authorize the Board of Directors to allot shares	474,984,226	10,910,963	131,376	--	24,764,077	98%	Not verified	—
10. To authorize the Board of Directors to allot shares without rights of pre-emption	455,564,249	30,278,595	183,721	--	24,764,077	94%	Not verified	—

Source: ROYALTY PHARMA PLC, Form 8-K, filed with the SEC on June 6, 2024 — read the filing on EDGAR.

How asset managers voted at the ROYALTY PHARMA PLC 2023-2024 meeting

Each item below shows how the 408 asset managers that disclosed a ROYALTY PHARMA PLC vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of ROYALTY PHARMA PLC’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. Elect Director: Bonnie Bassler, Ph.D.

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 8 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%

FOR: 480,331,728AGAINST: 5,609,040

Details: description as filed, official tally, votes by 98 asset managers

Description as filed by funds: Election of Directors: Bonnie Bassler , Ph.D.

ROYALTY PHARMA PLC’s own tally for this item (“Elect Director: Bonnie Bassler, Ph.D.”): 480,331,728 for, 5,609,040 against, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 98 asset managers below reported 121,435,773 for, 13,261 against, 45,346 abstained.

FOR

FOR: 121,435,773AGAINST: 13,261ABSTAIN: 45,346

Largest asset managers voting on “Election of Directors: Bonnie Bassler , Ph.D.” at ROYALTY PHARMA PLC, 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	38,139,554	0	For
Fidelity	33,129,635	0	For
Morgan Stanley	11,541,059	0	For
Putnam	7,017,976	0	For
BlackRock	5,728,038	0	For
JPMorgan	4,785,936	0	For
Transamerica	2,890,819	0	For
Brighthouse	1,856,012	16,248	For
Charles Schwab	1,773,729	0	For
Waddell & Reed	1,098,573	0	For
Advisor Managed Portfolios	997,944	0	For
TIAA	949,883	0	For
First Trust	927,223	0	For
Jackson National	864,686	0	For
JANUS INVESTMENT FUND	793,944	0	For
MUTUAL FUND SERIES TRUST	755,563	0	For
Eaton Vance	689,870	0	For
State Street	534,568	0	For
HOMESTEAD FUNDS INC	483,484	0	For
Victory Capital	454,919	0	For
Aberdeen	451,065	0	For
Principal	423,306	0	For
RBB Fund Trust	379,450	0	For
AB EQUITY INCOME FUND INC	366,869	0	For
BAILLIE GIFFORD FUNDS	362,925	0	For

Showing the 25 largest of 98 asset managers. See all 98 in the interactive database.

2. Elect Director: Catherine Engelbert

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 5 wordings of this item as funds reported it.

99.2% Majority: yes · of votes cast

FOR 99.2%

FOR: 482,164,279AGAINST: 3,725,318

Details: description as filed, official tally, votes by 98 asset managers

Description as filed by funds: Election of Directors: Catherine Engelbert

ROYALTY PHARMA PLC’s own tally for this item (“Elect Director: Catherine Engelbert”): 482,164,279 for, 3,725,318 against, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.2% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 98 asset managers below reported 121,015,178 for, 385,403 against, 93,799 abstained.

FOR

FOR: 121,015,178AGAINST: 385,403ABSTAIN: 93,799

Largest asset managers voting on “Election of Directors: Catherine Engelbert” at ROYALTY PHARMA PLC, 2023-2024
Asset manager	For	Against	Abstain	Vote
Vanguard	38,139,554	0	0	For
Fidelity	33,129,635	0	0	For
Morgan Stanley	11,541,059	0	0	For
Putnam	7,017,976	0	0	For
BlackRock	5,728,038	0	0	For
JPMorgan	4,785,936	0	0	For
Transamerica	2,890,819	0	0	For
Brighthouse	1,856,012	0	16,248	For
Charles Schwab	1,773,729	0	0	For
Waddell & Reed	1,098,573	0	0	For
Advisor Managed Portfolios	997,944	0	0	For
TIAA	949,883	0	0	For
First Trust	927,223	0	0	For
Jackson National	561,708	302,978	0	Mixed
JANUS INVESTMENT FUND	793,944	0	0	For
MUTUAL FUND SERIES TRUST	755,563	0	0	For
Eaton Vance	689,870	0	0	For
State Street	534,568	0	0	For
HOMESTEAD FUNDS INC	483,484	0	0	For
Victory Capital	454,919	0	0	For
Aberdeen	451,065	0	0	For
Principal	423,306	0	0	For
RBB Fund Trust	379,450	0	0	For
AB EQUITY INCOME FUND INC	366,869	0	0	For
BAILLIE GIFFORD FUNDS	362,925	0	0	For

Showing the 25 largest of 98 asset managers. See all 98 in the interactive database.

3. Elect Director: David Hodgson

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 5 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 474,265,799AGAINST: 11,668,945

Details: description as filed, official tally, votes by 98 asset managers

Description as filed by funds: Election of Directors: David Hodgson

ROYALTY PHARMA PLC’s own tally for this item (“Elect Director: David Hodgson”): 474,265,799 for, 11,668,945 against, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 98 asset managers below reported 121,050,633 for, 398,401 against, 45,346 abstained.

FOR

FOR: 121,050,633AGAINST: 398,401ABSTAIN: 45,346

Largest asset managers voting on “Election of Directors: David Hodgson” at ROYALTY PHARMA PLC, 2023-2024
Asset manager	For	Against	Abstain	Vote
Vanguard	38,139,554	0	0	For
Fidelity	33,129,635	0	0	For
Morgan Stanley	11,541,059	0	0	For
Putnam	7,017,976	0	0	For
BlackRock	5,728,038	0	0	For
JPMorgan	4,785,936	0	0	For
Transamerica	2,890,819	0	0	For
Brighthouse	1,856,012	0	16,248	For
Charles Schwab	1,773,729	0	0	For
Waddell & Reed	1,098,573	0	0	For
Advisor Managed Portfolios	997,944	0	0	For
TIAA	949,883	0	0	For
First Trust	927,223	0	0	For
Jackson National	561,708	302,978	0	Mixed
JANUS INVESTMENT FUND	793,944	0	0	For
MUTUAL FUND SERIES TRUST	755,563	0	0	For
Eaton Vance	689,870	0	0	For
State Street	534,568	0	0	For
HOMESTEAD FUNDS INC	483,484	0	0	For
Victory Capital	454,919	0	0	For
Aberdeen	451,065	0	0	For
Principal	423,306	0	0	For
RBB Fund Trust	379,450	0	0	For
AB EQUITY INCOME FUND INC	366,869	0	0	For
BAILLIE GIFFORD FUNDS	362,925	0	0	For

Showing the 25 largest of 98 asset managers. See all 98 in the interactive database.

4. Elect Director: Errol De Souza, Ph.D.

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 7 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 468,014,051AGAINST: 17,919,666

Details: description as filed, official tally, votes by 98 asset managers

Description as filed by funds: Election of Directors: Errol De Souza, Ph.D.

ROYALTY PHARMA PLC’s own tally for this item (“Elect Director: Errol De Souza, Ph.D.”): 468,014,051 for, 17,919,666 against, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 98 asset managers below reported 118,778,319 for, 2,670,715 against, 45,346 abstained.

FOR

FOR: 118,778,319AGAINST: 2,670,715ABSTAIN: 45,346

Largest asset managers voting on “Election of Directors: Errol De Souza, Ph.D.” at ROYALTY PHARMA PLC, 2023-2024
Asset manager	For	Against	Abstain	Vote
Vanguard	38,139,554	0	0	For
Fidelity	33,129,635	0	0	For
Morgan Stanley	11,541,059	0	0	For
Putnam	7,017,976	0	0	For
BlackRock	5,728,038	0	0	For
JPMorgan	4,785,936	0	0	For
Transamerica	2,890,819	0	0	For
Brighthouse	1,856,012	0	16,248	For
Charles Schwab	0	1,773,729	0	Against
Waddell & Reed	1,098,573	0	0	For
Advisor Managed Portfolios	950,000	47,944	0	For
TIAA	949,883	0	0	For
First Trust	927,223	0	0	For
Jackson National	864,686	0	0	For
JANUS INVESTMENT FUND	793,944	0	0	For
MUTUAL FUND SERIES TRUST	755,563	0	0	For
Eaton Vance	689,870	0	0	For
State Street	534,568	0	0	For
HOMESTEAD FUNDS INC	483,484	0	0	For
Victory Capital	454,919	0	0	For
Aberdeen	451,065	0	0	For
Principal	31,485	391,821	0	Mixed
RBB Fund Trust	379,450	0	0	For
AB EQUITY INCOME FUND INC	366,869	0	0	For
BAILLIE GIFFORD FUNDS	362,925	0	0	For

Showing the 25 largest of 98 asset managers. See all 98 in the interactive database.

5. Elect Director: Gregory Norden

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 6 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 472,819,630AGAINST: 13,114,794

Details: description as filed, official tally, votes by 98 asset managers

Description as filed by funds: Election of Directors: Gregory Norden

ROYALTY PHARMA PLC’s own tally for this item (“Elect Director: Gregory Norden”): 472,819,630 for, 13,114,794 against, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 98 asset managers below reported 120,644,730 for, 804,304 against, 45,346 abstained.

FOR

FOR: 120,644,730AGAINST: 804,304ABSTAIN: 45,346

Largest asset managers voting on “Election of Directors: Gregory Norden” at ROYALTY PHARMA PLC, 2023-2024
Asset manager	For	Against	Abstain	Vote
Vanguard	38,139,554	0	0	For
Fidelity	33,129,635	0	0	For
Morgan Stanley	11,541,059	0	0	For
Putnam	7,017,976	0	0	For
BlackRock	5,728,038	0	0	For
JPMorgan	4,785,936	0	0	For
Transamerica	2,890,819	0	0	For
Brighthouse	1,856,012	0	16,248	For
Charles Schwab	1,773,729	0	0	For
Waddell & Reed	1,098,573	0	0	For
Advisor Managed Portfolios	997,944	0	0	For
TIAA	949,883	0	0	For
First Trust	927,223	0	0	For
Jackson National	561,708	302,978	0	Mixed
JANUS INVESTMENT FUND	793,944	0	0	For
MUTUAL FUND SERIES TRUST	755,563	0	0	For
Eaton Vance	689,870	0	0	For
State Street	534,568	0	0	For
HOMESTEAD FUNDS INC	483,484	0	0	For
Victory Capital	454,919	0	0	For
Aberdeen	451,065	0	0	For
Principal	423,306	0	0	For
RBB Fund Trust	0	379,450	0	Against
AB EQUITY INCOME FUND INC	366,869	0	0	For
BAILLIE GIFFORD FUNDS	362,925	0	0	For

Showing the 25 largest of 98 asset managers. See all 98 in the interactive database.

6. Elect Director: Henry Fernandez

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 4 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 467,493,605AGAINST: 18,441,850

Details: description as filed, official tally, votes by 98 asset managers

Description as filed by funds: ELECTION OF DIRECTORS: Henry Fernandez

ROYALTY PHARMA PLC’s own tally for this item (“Elect Director: Henry Fernandez”): 467,493,605 for, 18,441,850 against, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 98 asset managers below reported 118,243,354 for, 3,205,680 against, 45,346 abstained.

FOR

FOR: 118,243,354AGAINST: 3,205,680ABSTAIN: 45,346

Largest asset managers voting on “ELECTION OF DIRECTORS: Henry Fernandez” at ROYALTY PHARMA PLC, 2023-2024
Asset manager	For	Against	Abstain	Vote
Vanguard	38,139,554	0	0	For
Fidelity	33,129,635	0	0	For
Morgan Stanley	11,541,059	0	0	For
Putnam	7,017,976	0	0	For
BlackRock	5,728,038	0	0	For
JPMorgan	4,785,936	0	0	For
Transamerica	2,890,819	0	0	For
Brighthouse	1,856,012	0	16,248	For
Charles Schwab	0	1,773,729	0	Against
Waddell & Reed	1,098,573	0	0	For
Advisor Managed Portfolios	950,000	47,944	0	For
TIAA	949,883	0	0	For
First Trust	927,223	0	0	For
Jackson National	561,708	302,978	0	Mixed
JANUS INVESTMENT FUND	793,944	0	0	For
MUTUAL FUND SERIES TRUST	755,563	0	0	For
Eaton Vance	689,870	0	0	For
State Street	534,568	0	0	For
HOMESTEAD FUNDS INC	483,484	0	0	For
Victory Capital	454,919	0	0	For
Aberdeen	451,065	0	0	For
Principal	31,485	391,821	0	Mixed
RBB Fund Trust	379,450	0	0	For
AB EQUITY INCOME FUND INC	366,869	0	0	For
BAILLIE GIFFORD FUNDS	362,925	0	0	For

Showing the 25 largest of 98 asset managers. See all 98 in the interactive database.

7. Elect Director: Pablo Legorreta

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 4 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 469,574,048AGAINST: 16,360,957

Details: description as filed, official tally, votes by 98 asset managers

Description as filed by funds: Election of Directors: Pablo Legorreta

ROYALTY PHARMA PLC’s own tally for this item (“Elect Director: Pablo Legorreta”): 469,574,048 for, 16,360,957 against, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 98 asset managers below reported 121,388,771 for, 263 against, 45,346 abstained.

FOR

FOR: 121,388,771AGAINST: 263ABSTAIN: 45,346

Largest asset managers voting on “Election of Directors: Pablo Legorreta” at ROYALTY PHARMA PLC, 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	38,139,554	0	For
Fidelity	33,129,635	0	For
Morgan Stanley	11,541,059	0	For
Putnam	7,017,976	0	For
BlackRock	5,728,038	0	For
JPMorgan	4,785,936	0	For
Transamerica	2,890,819	0	For
Brighthouse	1,856,012	16,248	For
Charles Schwab	1,773,729	0	For
Waddell & Reed	1,098,573	0	For
Advisor Managed Portfolios	997,944	0	For
TIAA	949,883	0	For
First Trust	927,223	0	For
Jackson National	864,686	0	For
JANUS INVESTMENT FUND	793,944	0	For
MUTUAL FUND SERIES TRUST	695,563	0	For
Eaton Vance	689,870	0	For
State Street	534,568	0	For
HOMESTEAD FUNDS INC	483,484	0	For
Victory Capital	454,919	0	For
Aberdeen	451,065	0	For
Principal	423,306	0	For
RBB Fund Trust	379,450	0	For
AB EQUITY INCOME FUND INC	366,869	0	For
BAILLIE GIFFORD FUNDS	362,925	0	For

Showing the 25 largest of 98 asset managers. See all 98 in the interactive database.

8. Elect Director: Ted Love, M.D.

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 6 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%

FOR: 457,219,827AGAINST: 28,488,315

Details: description as filed, official tally, votes by 98 asset managers

Description as filed by funds: Election of Directors: Ted Love , M.D.

ROYALTY PHARMA PLC’s own tally for this item (“Elect Director: Ted Love, M.D.”): 457,219,827 for, 28,488,315 against, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 98 asset managers below reported 119,317,839 for, 2,071,195 against, 45,346 abstained.

FOR

FOR: 119,317,839AGAINST: 2,071,195ABSTAIN: 45,346

Largest asset managers voting on “Election of Directors: Ted Love , M.D.” at ROYALTY PHARMA PLC, 2023-2024
Asset manager	For	Against	Abstain	Vote
Vanguard	38,139,554	0	0	For
Fidelity	33,129,635	0	0	For
Morgan Stanley	11,535,322	5,737	0	For
Putnam	7,017,976	0	0	For
BlackRock	5,728,038	0	0	For
JPMorgan	4,785,936	0	0	For
Transamerica	2,890,819	0	0	For
Brighthouse	1,856,012	0	16,248	For
Charles Schwab	1,773,729	0	0	For
Waddell & Reed	0	1,098,573	0	Against
Advisor Managed Portfolios	997,944	0	0	For
TIAA	949,883	0	0	For
First Trust	927,223	0	0	For
Jackson National	864,686	0	0	For
JANUS INVESTMENT FUND	793,944	0	0	For
MUTUAL FUND SERIES TRUST	695,563	0	0	For
Eaton Vance	689,870	0	0	For
State Street	0	534,568	0	Against
HOMESTEAD FUNDS INC	483,484	0	0	For
Victory Capital	454,919	0	0	For
Aberdeen	451,065	0	0	For
Principal	423,306	0	0	For
RBB Fund Trust	379,450	0	0	For
AB EQUITY INCOME FUND INC	366,869	0	0	For
BAILLIE GIFFORD FUNDS	362,925	0	0	For

Showing the 25 largest of 98 asset managers. See all 98 in the interactive database.

9. 10. To authorize the Board of Directors to allot shares without rights of pre-emption

Outcome not verifiedCAPITAL STRUCTUREReported outcome: Not verified

Combines 4 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%

FOR: 455,564,249AGAINST: 30,278,595

Details: description as filed, official tally, votes by 97 asset managers

Description as filed by funds: Authorize the Board to allot shares without rights of pre- emption (special resolution).

ROYALTY PHARMA PLC’s own tally for this item (“10. To authorize the Board of Directors to allot shares without rights of pre-emption”): 455,564,249 for, 30,278,595 against, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 97 asset managers below reported 119,525,855 for, 1,965,158 against.

FOR

FOR: 119,525,855AGAINST: 1,965,158

Largest asset managers voting on “Authorize the Board to allot shares without rights of pre- emption (special resolution).” at ROYALTY PHARMA PLC, 2023-2024
Asset manager	For	Against	Vote
Vanguard	36,727,871	1,411,683	For
Fidelity	33,129,635	0	For
Morgan Stanley	11,541,059	0	For
Putnam	7,017,976	0	For
BlackRock	5,728,038	0	For
JPMorgan	4,785,936	0	For
Transamerica	2,890,819	0	For
Brighthouse	1,856,012	16,248	For
Charles Schwab	1,773,729	0	For
Waddell & Reed	1,098,573	0	For
Advisor Managed Portfolios	997,944	0	For
TIAA	949,883	0	For
First Trust	927,223	0	For
Jackson National	864,686	0	For
JANUS INVESTMENT FUND	793,944	0	For
MUTUAL FUND SERIES TRUST	755,563	0	For
Eaton Vance	689,870	0	For
State Street	534,568	0	For
HOMESTEAD FUNDS INC	483,484	0	For
Victory Capital	454,919	0	For
Aberdeen	451,065	0	For
Principal	423,306	0	For
RBB Fund Trust	379,450	0	For
AB EQUITY INCOME FUND INC	366,869	0	For
BAILLIE GIFFORD FUNDS	0	362,925	Against

Showing the 25 largest of 97 asset managers. See all 97 in the interactive database.

10. Authorize the Board to allot shares.

No official matchCAPITAL STRUCTURE

Combines 3 wordings of this item as funds reported it.

99.9% of fund votes cast · no official result

FOR

Details: votes by 97 asset managers

The 97 asset managers below reported 121,449,478 for, 41,535 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 121,449,478AGAINST: 41,535

Largest asset managers voting on “Authorize the Board to allot shares.” at ROYALTY PHARMA PLC, 2023-2024
Asset manager	For	Against	Vote
Vanguard	38,139,554	0	For
Fidelity	33,129,635	0	For
Morgan Stanley	11,541,059	0	For
Putnam	7,017,976	0	For
BlackRock	5,728,038	0	For
JPMorgan	4,785,936	0	For
Transamerica	2,890,819	0	For
Brighthouse	1,856,012	16,248	For
Charles Schwab	1,773,729	0	For
Waddell & Reed	1,098,573	0	For
Advisor Managed Portfolios	997,944	0	For
TIAA	949,883	0	For
First Trust	927,223	0	For
Jackson National	864,686	0	For
JANUS INVESTMENT FUND	793,944	0	For
MUTUAL FUND SERIES TRUST	755,563	0	For
Eaton Vance	689,870	0	For
State Street	534,568	0	For
HOMESTEAD FUNDS INC	483,484	0	For
Victory Capital	454,919	0	For
Aberdeen	451,065	0	For
Principal	423,306	0	For
RBB Fund Trust	379,450	0	For
AB EQUITY INCOME FUND INC	366,869	0	For
BAILLIE GIFFORD FUNDS	362,925	0	For

Showing the 25 largest of 97 asset managers. See all 97 in the interactive database.

11. 2. To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers

Outcome not verified Fund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Not verified

Combines 12 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%

FOR: 448,091,225AGAINST: 37,716,521

Details: description as filed, official tally, votes by 408 asset managers

Description as filed by funds: A non-binding advisory vote to approve executive compensation.

ROYALTY PHARMA PLC’s own tally for this item (“2. To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers”): 448,091,225 for, 37,716,521 against, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 97 asset managers voting on “A non-binding advisory vote to approve executive compensation.” at ROYALTY PHARMA PLC, 2023-2024
Asset manager	For	Against	Abstain	Vote
Vanguard	38,139,554	0	0	For
Fidelity	33,129,635	0	0	For
Morgan Stanley	11,541,059	0	0	For
Putnam	0	7,017,976	0	Against
BlackRock	5,728,038	0	0	For
JPMorgan	0	4,785,936	0	Against
Transamerica	2,882,812	8,007	0	For
Brighthouse	1,856,011	1	16,248	For
Charles Schwab	1,773,729	0	0	For
Waddell & Reed	1,098,573	0	0	For
Advisor Managed Portfolios	950,000	47,944	0	For
TIAA	949,883	0	0	For
First Trust	927,223	0	0	For
Jackson National	302,978	561,708	0	Mixed
JANUS INVESTMENT FUND	793,944	0	0	For
MUTUAL FUND SERIES TRUST	695,563	0	0	For
Eaton Vance	689,870	0	0	For
State Street	534,568	0	0	For
HOMESTEAD FUNDS INC	483,484	0	0	For
Victory Capital	454,919	0	0	For
Aberdeen	451,065	0	0	For
Principal	31,485	391,821	0	Mixed
RBB Fund Trust	379,450	0	0	For
AB EQUITY INCOME FUND INC	366,869	0	0	For
BAILLIE GIFFORD FUNDS	362,925	0	0	For

Fund voting reports, all 97 managers: 107,471,883 for, 14,093,606 against, 18,537 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 338 asset managers voting on “A non-binding advisory vote to approve executive compensation.” at ROYALTY PHARMA PLC, 2023-2024
Asset manager	For	Against	Vote
Morgan Stanley	35,191,783	0	For
Fidelity	31,225,453	0	For
BlackRock	14,412,765	3,847	For
VIKING GLOBAL INVESTORS LP	11,543,720	0	For
ADAGE CAPITAL PARTNERS GP, L.L.C.	10,816,931	0	For
Swedbank Robur Fonder AB	0	8,383,000	Against
State Street	7,447,990	0	For
JPMorgan	231	6,967,823	Against
GEODE CAPITAL MANAGEMENT, LLC	6,552,228	0	For
BAILLIE GIFFORD & CO LTD	4,199,306	0	For
BAILLIE GIFFORD OVERSEAS LTD	3,592,717	61,873	For
Northern Trust	2,751,697	0	For
John Hancock	2,652,689	0	For
Amundi	267,860	1,920,425	Mixed
GENERAL ATLANTIC, L.P.	2,055,039	0	For
CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM	0	2,014,933	Against
NEW SOUTH CAPITAL MANAGEMENT INC	1,922,447	0	For
HOMESTEAD ADVISERS CORP	1,892,540	0	For
GMT CAPITAL CORP	0	1,884,988	Against
Janus Henderson	1,882,289	0	For
Charles Schwab	1,841,789	0	For
London LGPS CIV Ltd	1,820,182	0	For
Legal & General Investment Management Ltd	0	1,804,585	Against
SUVRETTA CAPITAL MANAGEMENT, LLC	1,632,947	0	For
Man Group plc	0	1,473,940	Against

Institutional-manager reports, all 338 managers: 173,455,967 for, 35,447,038 against, 39,884 abstained, 2,027 not voted, 163 unknown. Showing the 25 largest; see all in the interactive database.

12. 6. To approve, on a non-binding advisory basis, the Company's U.K. directors' remuneration report in the U.K. Annual…

Outcome not verified Fund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Not verified

Combines 9 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%

FOR: 448,684,306AGAINST: 37,116,575

Details: description as filed, official tally, votes by 187 asset managers

Description as filed by funds: Approve on a non-binding advisory basis our U.K. directors' remuneration report (other than the part containing the directors' remuneration policy) for the fiscal year ended December 31, 2023

ROYALTY PHARMA PLC’s own tally for this item (“6. To approve, on a non-binding advisory basis, the Company's U.K. directors' remuneration report in the U.K. Annual Report and Accounts”): 448,684,306 for, 37,116,575 against, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Fund voting reports: 95 asset managers voting on “Approve on a non-binding advisory basis our U.K. directors' remuneration report (other than the part containin” at ROYALTY PHARMA PLC, 2023-2024
Asset manager	For	Against	Abstain	Vote
Vanguard	38,139,554	0	0	For
Fidelity	33,129,635	0	0	For
Morgan Stanley	11,541,059	0	0	For
Putnam	0	7,017,976	0	Against
BlackRock	5,728,038	0	0	For
JPMorgan	0	4,785,936	0	Against
Transamerica	2,882,812	8,007	0	For
Brighthouse	1,856,011	1	16,248	For
Charles Schwab	1,773,729	0	0	For
Waddell & Reed	1,098,573	0	0	For
Advisor Managed Portfolios	950,000	47,944	0	For
TIAA	949,883	0	0	For
First Trust	927,223	0	0	For
Jackson National	302,978	561,708	0	Mixed
JANUS INVESTMENT FUND	793,944	0	0	For
MUTUAL FUND SERIES TRUST	755,563	0	0	For
Eaton Vance	689,870	0	0	For
State Street	534,568	0	0	For
HOMESTEAD FUNDS INC	483,484	0	0	For
Victory Capital	454,919	0	0	For
Aberdeen	451,065	0	0	For
Principal	31,485	391,821	0	Mixed
RBB Fund Trust	379,450	0	0	For
AB EQUITY INCOME FUND INC	366,869	0	0	For
BAILLIE GIFFORD FUNDS	362,925	0	0	For

Fund voting reports, all 95 managers: 107,894,808 for, 13,579,462 against, 16,248 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 94 asset managers voting on “Approve on a non-binding advisory basis our U.K. directors' remuneration report (other than the part containin” at ROYALTY PHARMA PLC, 2023-2024
Asset manager	For	Against	Abstain	Vote
BAILLIE GIFFORD & CO LTD	4,199,306	0	0	For
BAILLIE GIFFORD OVERSEAS LTD	3,592,717	61,873	0	For
Northern Trust	2,751,697	0	0	For
NEW SOUTH CAPITAL MANAGEMENT INC	1,922,447	0	0	For
GMT CAPITAL CORP	0	1,884,988	0	Against
RAYMOND JAMES & ASSOCIATES	0	736,307	0	Against
PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC.	329,499	0	0	For
Portolan Capital Management, LLC	287,157	0	0	For
TORRAY INVESTMENT PARTNERS LLC	272,299	0	0	For
JPMorgan	231	232,678	0	Against
EVERGREEN CAPITAL MANAGEMENT LLC	229,940	0	0	For
Overbrook Management Corp	0	209,268	0	Against
J. Goldman & Co LP	178,388	0	0	For
Ensign Peak Advisors, Inc	177,867	0	0	For
Baillie Gifford Investment Management (Europe) Ltd	176,320	0	0	For
Treasurer of the State of North Carolina	0	175,879	0	Against
Korea Investment CORP	173,748	0	0	For
Corient Private Wealth LLC	110,704	205	0	For
Kovitz Investment Group Partners, LLC	102,383	576	0	For
CAISSE DE DEPOT ET PLACEMENT DU QUEBEC	92,452	0	0	For
EASTERN BANK	56,838	0	0	For
ENVESTNET ASSET MANAGEMENT INC	0	43,482	0	Against
Aurora Investment Counsel	0	0	39,884	Abstain
Ridgewood Investments LLC	31,090	0	0	For
ROCKEFELLER FINANCIAL LLC	19,977	0	0	For

Institutional-manager reports, all 94 managers: 14,813,423 for, 3,430,451 against, 39,884 abstained, 163 unknown. Showing the 25 largest; see all in the interactive database.

13. 5. To approve, the Company's U.K. directors' remuneration policy, included in U.K. directors' remuneration report…

Outcome not verifiedCOMPENSATIONCORPORATE GOVERNANCEReported outcome: Not verified

Combines 7 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%

FOR: 446,941,633AGAINST: 38,920,774

Details: description as filed, official tally, votes by 103 asset managers

Description as filed by funds: Approve our U.K. directors' remuneration policy.

ROYALTY PHARMA PLC’s own tally for this item (“5. To approve, the Company's U.K. directors' remuneration policy, included in U.K. directors' remuneration report contained in the U.K. Annual Report and Accounts”): 446,941,633 for, 38,920,774 against, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 103 asset managers below reported 106,225,028 for, 15,359,761 against, 18,537 abstained.

FOR

FOR: 106,225,028AGAINST: 15,359,761ABSTAIN: 18,537

Largest asset managers voting on “Approve our U.K. directors' remuneration policy.” at ROYALTY PHARMA PLC, 2023-2024
Asset manager	For	Against	Abstain	Vote
Vanguard	38,139,554	0	0	For
Fidelity	33,129,635	0	0	For
Morgan Stanley	11,541,059	0	0	For
Putnam	0	7,017,976	0	Against
BlackRock	5,728,038	0	0	For
JPMorgan	0	4,785,936	0	Against
Transamerica	2,882,812	8,007	0	For
Brighthouse	1,856,011	1	16,248	For
Charles Schwab	0	1,773,729	0	Against
Waddell & Reed	1,098,573	0	0	For
Advisor Managed Portfolios	950,000	47,944	0	For
TIAA	949,883	0	0	For
First Trust	927,223	0	0	For
Jackson National	302,978	561,708	0	Mixed
JANUS INVESTMENT FUND	793,944	0	0	For
MUTUAL FUND SERIES TRUST	755,563	0	0	For
Eaton Vance	689,870	0	0	For
State Street	534,568	0	0	For
HOMESTEAD FUNDS INC	483,484	0	0	For
Victory Capital	454,919	0	0	For
Aberdeen	451,065	0	0	For
Principal	31,485	391,821	0	Mixed
RBB Fund Trust	379,450	0	0	For
AB EQUITY INCOME FUND INC	366,869	0	0	For
BAILLIE GIFFORD FUNDS	362,925	0	0	For

Showing the 25 largest of 103 asset managers. See all 103 in the interactive database.

14. 8. To authorize the Board of Directors to determine the remuneration of the Company's U.K. statutory auditor

Outcome not verifiedAUDIT-RELATEDReported outcome: Not verified

Combines 7 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 485,875,260AGAINST: 100,511

Details: description as filed, official tally, votes by 99 asset managers

Description as filed by funds: Authorize the Board to determine the remuneration of Ernst & Young in its capacity as our U.K. statutory auditor.

ROYALTY PHARMA PLC’s own tally for this item (“8. To authorize the Board of Directors to determine the remuneration of the Company's U.K. statutory auditor”): 485,875,260 for, 100,511 against, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 99 asset managers below reported 121,462,845 for, 12,998 against, 18,537 abstained.

FOR

FOR: 121,462,845AGAINST: 12,998ABSTAIN: 18,537

Largest asset managers voting on “Authorize the Board to determine the remuneration of Ernst & Young in its capacity as our U.K. statutory audit” at ROYALTY PHARMA PLC, 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	38,139,554	0	For
Fidelity	33,129,635	0	For
Morgan Stanley	11,541,059	0	For
Putnam	7,017,976	0	For
BlackRock	5,728,038	0	For
JPMorgan	4,785,936	0	For
Transamerica	2,890,819	0	For
Brighthouse	1,856,012	16,248	For
Charles Schwab	1,773,729	0	For
Waddell & Reed	1,098,573	0	For
Advisor Managed Portfolios	997,944	0	For
TIAA	949,883	0	For
First Trust	927,223	0	For
Jackson National	864,686	0	For
JANUS INVESTMENT FUND	793,944	0	For
MUTUAL FUND SERIES TRUST	755,563	0	For
Eaton Vance	689,870	0	For
State Street	534,568	0	For
HOMESTEAD FUNDS INC	483,484	0	For
Victory Capital	454,919	0	For
Aberdeen	451,065	0	For
Principal	423,306	0	For
RBB Fund Trust	379,450	0	For
AB EQUITY INCOME FUND INC	366,869	0	For
BAILLIE GIFFORD FUNDS	362,925	0	For

Showing the 25 largest of 99 asset managers. See all 99 in the interactive database.

15. 3. To ratify the appointment of Ernst & Young LLP, as the Company's independent registered public accounting firm

Outcome not verifiedAUDIT-RELATEDReported outcome: Not verified

Combines 8 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 510,538,774AGAINST: 175,866

Details: description as filed, official tally, votes by 99 asset managers

Description as filed by funds: Ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm.

ROYALTY PHARMA PLC’s own tally for this item (“3. To ratify the appointment of Ernst & Young LLP, as the Company's independent registered public accounting firm”): 510,538,774 for, 175,866 against, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 99 asset managers below reported 121,612,986 for, 12,998 against, 18,537 abstained.

FOR

FOR: 121,612,986AGAINST: 12,998ABSTAIN: 18,537

Largest asset managers voting on “Ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm.” at ROYALTY PHARMA PLC, 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	38,139,554	0	For
Fidelity	33,129,635	0	For
Morgan Stanley	11,541,059	0	For
Putnam	7,017,976	0	For
BlackRock	5,728,038	0	For
JPMorgan	4,785,936	0	For
Transamerica	2,890,819	0	For
Brighthouse	1,856,012	16,248	For
Charles Schwab	1,773,729	0	For
Waddell & Reed	1,098,573	0	For
Advisor Managed Portfolios	997,944	0	For
TIAA	949,883	0	For
First Trust	927,223	0	For
Jackson National	864,686	0	For
JANUS INVESTMENT FUND	793,944	0	For
MUTUAL FUND SERIES TRUST	755,563	0	For
Eaton Vance	689,870	0	For
State Street	534,568	0	For
HOMESTEAD FUNDS INC	483,484	0	For
Victory Capital	454,919	0	For
Aberdeen	451,065	0	For
Principal	423,306	0	For
RBB Fund Trust	379,450	0	For
AB EQUITY INCOME FUND INC	366,869	0	For
BAILLIE GIFFORD FUNDS	362,925	0	For

Showing the 25 largest of 99 asset managers. See all 99 in the interactive database.

16. 4. To approve receipt of the Company's U.K. statutory accounts together with the Company's U.K. statutory reports…

Outcome not verifiedOTHERReported outcome: Not verified

Combines 6 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 510,158,489AGAINST: 64,644

Details: description as filed, official tally, votes by 98 asset managers

Description as filed by funds: Approve receipt of our U.K. audited annual report and accounts and related directors' and auditor's reports for the fiscal year ended December 31, 2023.

ROYALTY PHARMA PLC’s own tally for this item (“4. To approve receipt of the Company's U.K. statutory accounts together with the Company's U.K. statutory reports, including the directors' report, the strategic report, the directors' remuneration report and the auditor”): 510,158,489 for, 64,644 against, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 98 asset managers below reported 121,624,906 for, 16,248 abstained.

FOR

FOR: 121,624,906ABSTAIN: 16,248

Largest asset managers voting on “Approve receipt of our U.K. audited annual report and accounts and related directors' and auditor's reports fo” at ROYALTY PHARMA PLC, 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	38,139,554	0	For
Fidelity	33,129,635	0	For
Morgan Stanley	11,541,059	0	For
Putnam	7,017,976	0	For
BlackRock	5,728,038	0	For
JPMorgan	4,785,936	0	For
Transamerica	2,890,819	0	For
Brighthouse	1,856,012	16,248	For
Charles Schwab	1,773,729	0	For
Waddell & Reed	1,098,573	0	For
Advisor Managed Portfolios	997,944	0	For
TIAA	949,883	0	For
First Trust	927,223	0	For
Jackson National	864,686	0	For
JANUS INVESTMENT FUND	793,944	0	For
MUTUAL FUND SERIES TRUST	755,563	0	For
Eaton Vance	689,870	0	For
State Street	534,568	0	For
HOMESTEAD FUNDS INC	483,484	0	For
Victory Capital	454,919	0	For
Aberdeen	451,065	0	For
Principal	423,306	0	For
RBB Fund Trust	379,450	0	For
AB EQUITY INCOME FUND INC	366,869	0	For
BAILLIE GIFFORD FUNDS	362,925	0	For

Showing the 25 largest of 98 asset managers. See all 98 in the interactive database.

17. 7. To re-appoint Ernst & Young Chartered Accountants as the Company's U.K. statutory auditor under the U.K. Companies…

Outcome not verifiedAUDIT-RELATEDReported outcome: Not verified

Combines 7 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 510,533,472AGAINST: 190,241

Details: description as filed, official tally, votes by 98 asset managers

Description as filed by funds: Re-appoint Ernst & Young as our U.K. statutory auditor, to hold office until the conclusion of the next general meeting at which the U.K. annual report and accounts are presented to shareholders.

ROYALTY PHARMA PLC’s own tally for this item (“7. To re-appoint Ernst & Young Chartered Accountants as the Company's U.K. statutory auditor under the U.K. Companies Act 2006, to hold office until the conclusion of the next general meeting of shareholders at which the”): 510,533,472 for, 190,241 against, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 98 asset managers below reported 121,462,845 for, 12,998 against, 18,537 abstained.

FOR

FOR: 121,462,845AGAINST: 12,998ABSTAIN: 18,537

Largest asset managers voting on “Re-appoint Ernst & Young as our U.K. statutory auditor, to hold office until the conclusion of the next genera” at ROYALTY PHARMA PLC, 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	38,139,554	0	For
Fidelity	33,129,635	0	For
Morgan Stanley	11,541,059	0	For
Putnam	7,017,976	0	For
BlackRock	5,728,038	0	For
JPMorgan	4,785,936	0	For
Transamerica	2,890,819	0	For
Brighthouse	1,856,012	16,248	For
Charles Schwab	1,773,729	0	For
Waddell & Reed	1,098,573	0	For
Advisor Managed Portfolios	997,944	0	For
TIAA	949,883	0	For
First Trust	927,223	0	For
Jackson National	864,686	0	For
JANUS INVESTMENT FUND	793,944	0	For
MUTUAL FUND SERIES TRUST	755,563	0	For
Eaton Vance	689,870	0	For
State Street	534,568	0	For
HOMESTEAD FUNDS INC	483,484	0	For
Victory Capital	454,919	0	For
Aberdeen	451,065	0	For
Principal	423,306	0	For
RBB Fund Trust	379,450	0	For
AB EQUITY INCOME FUND INC	366,869	0	For
BAILLIE GIFFORD FUNDS	362,925	0	For

Showing the 25 largest of 98 asset managers. See all 98 in the interactive database.

Largest ROYALTY PHARMA PLC shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 448,623,000 shares outstanding at the time of that meeting.

Fund voting reports: top ROYALTY PHARMA PLC shareholders by shares voted on “A non-binding advisory vote to approve executive compensation.”, 2023-2024
#	Asset manager	% of shares outstanding
1	Vanguard	8.50%
2	Fidelity	7.38%
3	Morgan Stanley	2.57%
4	Putnam	1.56%
5	BlackRock	1.28%
6	JPMorgan	1.07%
7	Transamerica	0.64%
8	Brighthouse	0.42%
9	Charles Schwab	0.40%
10	Waddell & Reed	0.24%

Institutional-manager reports: top ROYALTY PHARMA PLC shareholders by shares voted on “A non-binding advisory vote to approve executive compensation.”, 2023-2024
#	Asset manager	% of shares outstanding
1	Morgan Stanley	7.84%
2	Fidelity	6.96%
3	BlackRock	3.21%
4	VIKING GLOBAL INVESTORS LP	2.57%
5	ADAGE CAPITAL PARTNERS GP, L.L.C.	2.41%
6	Swedbank Robur Fonder AB	1.87%
7	State Street	1.66%
8	JPMorgan	1.55%
9	GEODE CAPITAL MANAGEMENT, LLC	1.46%
10	BAILLIE GIFFORD & CO LTD	0.94%

Reported ROYALTY PHARMA PLC holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

ROYALTY PHARMA PLC holdings and ownership disclosed for the 2023-2024 proxy season
Holder	% outstanding	Disclosure
Continuing US Investors Partnership	32.34%	DEF14A
GISEV Trustees Limited	9.73%	DEF14A
Morgan Stanley	9.17%	DEF14A
FMR LLC	7.04%	DEF14A
FMR (Fidelity)	6.24%	13F
BlackRock	5.84%	13F
Vanguard Group	2.44%	13F
M. Germano Giuliani	2.30%	DEF14A
State Street	2.03%	13F
Geode Capital	1.46%	13F

Percentages above are of 448,623,000 shares outstanding, as reported by ROYALTY PHARMA PLC on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ROYALTY PHARMA PLC’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on November 1, 2026; a live search always shows the current data.

At ROYALTY PHARMA PLC's shareholder meeting held June 6, 2024, in the 2023-2024 proxy season, 408 asset managers reported how they voted in their SEC Form N-PX filings, covering 7,337 separate fund positions. Their filings are grouped here into 17 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — A non-binding advisory vote to approve executive compensation. — FOR was 92% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: ROYALTY PHARMA PLC's Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 6, 2024.

ROYALTY PHARMA PLC proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.

Download data (CSV): ballot items · votes by manager · column guide.